AbbVie could be heading for its second acquisition in the space of a month, with reports emerging of late-stage negotiations with Gilgamesh Pharmaceuticals, a central nervous system (CNS) drug ...

AbbVie has filed for approval of a regimen based on its Venclexta therapy for previously untreated patients with chronic lymphocytic leukaemia (CLL), in combination with an AstraZeneca drug. The ...